Table 2 Baseline characteristics of the replication cohort of sarcoidosis patients with pulmonary treatment indication
Parameter | Prednisone treated group | Methotrexate treated group | |||
|---|---|---|---|---|---|
Non-responding (n = 20) | Responding (n = 29) | Non-responding (n = 38) | Responding (n = 42) | ||
Agea (years) | 43.6 ± 10.0 | 43.5 ± 9.6 | 49.0 ± 10.0 | 47.9 ± 10.9 | |
Male sex | 14 (70.0) | 21 (72.4) | 23 (71.9) | 25 (59.5) | |
Ever smoker | 5 (31.3) | 10 (47.6) | 15 (60.0) | 18 (52.9) | |
Caucasian | 18 (90.0) | 26 (92.9) | 28 (90.3) | 36 (90.0) | |
Lofgren syndrome | 0 (0.0) | 2 (7.1) | 2 (6.3) | 2 (4.8) | |
Scadding stageb 0/I/II/III/IV | 0/2/12/1/4 (0/11/63/5/21) | 0/5/14/1/7 (0/19/52/4/26) | 2/3/11/1/12 (7/10/38/3/4130) | 2/7/18/0/7 (6/20/53/0/21) | |
Lung functionb | |||||
FVC (%) | 94.5 ± 19.1 | 83.5 ± 20.4 | 97.1 ± 22.2 | 91.1 ± 23.1 | |
DLCO (%) | 70.3 ± 16.3 | 66.6 ± 17.8 | 72.3 ± 15.0 | 67.7 ± 15.5 | |
Extra-pulmonary involvement | |||||
Lymph nodes | 12 (60.0) | 16 (55.2) | 22 (68.8) | 28 (66.7) | |
Skin | 0 (0.0) | 3 (10.3) | 6 (18.8) | 4 (9.5) | |
Liver | 1 (5.0) | 1 (3.4) | 5 (15.6) | 6 (14.3) | |
Spleen | 5 (25.0) | 5 (17.2) | 7 (21.9) | 7 (16.7) | |
SFN | 4 (20.0) | 2 (6.9) | 5 (15.6) | 3 (7.1) | |